Phase II Trial of Simple Oral Therapy with Capecitabine and Cyclophosphamide in Patients with Metastatic Breast Cancer: SWOG S0430 Journal Article

Local Library Link: Find It @ Loyola

Authors: Schott, A. F.; Barlow, W. E.; Albain, K. S.; Chew, H. K.; Wade, J. L.; Lanier, K. S.; Lew, D. L.; Hayes, D. F.; Gralow, J. R.; Livingston, R. B.; Hortobagyi, G. N.
Article Title: Phase II Trial of Simple Oral Therapy with Capecitabine and Cyclophosphamide in Patients with Metastatic Breast Cancer: SWOG S0430
Abstract: Background. Interest in oral agents for the treatment of metastatic breast cancer (MBC) has increased because many patients prefer oral to i.v. regimens. We evaluated a simple oral combination of capecitabine with cyclophosphamide (CPA) for MBC. Methods. The trial was designed to determine whether or not combination therapy would achieve a 42% response rate (RR) using the Response Evaluation Criteria in Solid Tumors (RECIST) in MBC. Patients with two or fewer prior chemotherapy regimens for MBC were eligible. Those with estrogen receptor-positive MBC had to have progressed on endocrine therapy. Patients had measurable disease or elevated mucin (MUC)-1 antigen and received CPA, 100 mg daily on days 1-14, and capecitabine, 1,500 mg twice daily on days 8-21, in 21-day cycles. Results. In 96 eligible patients, the median progression-free survival (PFS) interval was 5.9 months (95% confidence interval [CI], 3.7- 8.0 months) and median overall survival (OS) time was 18.8 months (95% CI, 13.1-22.0 months). The RR was 36% (95% CI, 26%-48%) in 80 patients with measurable disease. The MUC-1 antigen RR was 33% (95% CI, 20%-48%), occurring in 15 of 46 patients with elevated MUC-1 antigen. Toxicity was mild, with no treatment-related deaths. Conclusions. PFS, OS, and RR outcomes with capecitabine plus CPA compare favorably with those of capecitabine monotherapy and combination therapy with bevacizumab, sorafenib, or ixabepilone. The addition of these other agents to capecitabine does not improve OS time in MBC patients, and this single-arm study does not suggest that the addition of CPA to capecitabine has this potential in an unselected MBC population. When OS prolongation is the goal, clinicians should choose single-agent capecitabine.
Journal Title: Oncologist
Volume: 17
Issue: 2
ISSN: CE pg 179 (website); 1083-7159
Publisher: Unknown  
Date Published: 2012
Start Page: 179
End Page: 188
Language: English
DOI/URL:

http://search.ebscohost.com/login.aspx?direct=true=rzh=2011512699=ehost-live

http://search.ebscohost.com/login.aspx?direct=true=rzh=2011512699=ehost-live

10.1634/theoncologist.2011-0235
Notes: ID: 12338; JS: Biomedical; JS: Blind Peer Reviewed; JS: Editorial Board Reviewed; JS: Expert Peer Reviewed; JS: Online/Print; JS: Peer Reviewed; JS: USA; GI: This investigation was supported in part by the following PHS Cooperative Agreement grants awarded by the National Cancer Institute, DHHS: CA32102, CA38926, CA46441, CA45807, CA46282, CA45377, CA27057, CA45808, CA20319, CA76447, CA42777, CA12644, CA95860, CA04919, CA35128, CA11083, CA58882, CA35192, CA35176, CA45461, CA35281, CA63844, CA22433, CA58861, and CA67575.; EM: 20120511